Farmakoterapia bólu neuropatycznego u psów i kotów

Piśmiennictwo

1. Szczudlik A., Dobrogowski J., Wordliczek J., Stępień A., Krajnik M., Leppert W., Woroń J., Przeklasa-Muszyńska A., Kocot-Kępska M., Zajączkowska R., Janecki M., Adamczyk A., Malec-Milewska M.: Rozpoznanie i leczenie bólu neuropatycznego: przegląd piśmiennictwa i zalecenia Polskiego Towarzystwa Badania Bólu i Towarzystwa Neurologicznego – część pierwsza. „Ból”, 2014, 15, 2, 8-18, DOI: 10.5604/1640324x.1115164.
2. Bennett M.I., Rayment C., Hjermstad M., Aass N., Caraceni A., Kaasa S.: Prevalence and aetiology of neuropathic pain in cancer patients: A systematic review. „Pain”, 2012, 153, 359-365.
3. Boldt I., Eriks-Hoogland I., Brinkhof M.W., de Bie R., Joggi D., von Elm E.: Non-pharmacological interventions for chronic pain in people with spinal cord injury. „Cochrane Database Syst Rev”, 2014, 11, CD009177. DOI: 10.1002/14651858.CD009177.
4. Gilron I., Baron R., Jensen T.: Neuropathic pain: principles of diagnosis and treatment. „Mayo Clin Proc”, 2015, 4, 532-45. DOI: 10.1016/j.mayocp.2015.01.018.
5. Woolf C.J.: What is this thing called pain? „J Clin Invest”, 2010, 120 (11), 3742-4. DOI: 10.1172/JCI45178 (Epub 2010 Nov 1).
6. Ruel H.L.M., Watanabe R., Evangelista M.C., Beauchamp G., Auger J.P., Segura M., Steagall P.V.: Pain burden, sensory profile, and inflammatory cytokines of dogs with naturally occurring neuropathic pain treated with gabapentin alone or with meloxicam. 2020, 30, 15 (11), e0237121. DOI: 10.1371/journal.pone.0237121 (eCollection 2020).
7. Gilron I., Jensen T.S., Dickenson A.H.: Combination pharmacotherapy for management of chronic pain: from bench to bedside. „Lancet Neurol”, 2013 Nov, 12 (11), 1084-95. DOI: 10.1016/S1474-4422(13)70193-5. Epub 2013 Sep 25.
8. Finnerup N.B., Sindrup S.H., Jensen T.S.: The evidence for pharmacological treatment of neuropathic pain. „Pain”, 2010, 150 (3), 573-581. DOI: 10.1016/j.pain.2010.06.019.
9. Harriott B.S., Gold M.S.: Contribution of primary afferent channels to neuropathic pain. „Curr Pain Headache Rep”, 2009, 13, 197-207.
10. Xua Q., Yaksh T.L.: A brief comparison of the pathophysiology of inflammatory versus neuropathic pain. „Curr Opin Anaesthesiol”, 2011, 24, 400-407.
11. Park J.S., Voitenko N., Petralia R.S. et al.: Persistent inflammation induces GluR2 internalization via NMDA receptor – triggered PKC activation in dorsal horn neurons. „J Neurosci”, 2009, 29, 3206-3219.
12. Liu F., Yuan H.: Role of glia in neuropathic pain. ”Front Biosci (Landmark Ed)”, 2014, 19, 798-807. DOI: 10.2741/4247.
13. Olmarker K., Rydevik B.: Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. „Spine”, 2001, 26, 863-9. DOI: 10.1097/00007632-200104150-00007.
14. Quintao N.L., Balz D., Santos A.R., Campos M.M., Calixto J.B.: Long-lasting neuropathic pain induced by brachial plexus injury in mice: role triggered by the pro-inflammatory cytokine, tumour necrosis factor alpha. „Neuropharmacology”, 2006, 50, 614-20. DOI: 10.1016/j.neuropharm.2005.11.007.
15. Wordliczek J., Zajączkowska R., Leppert W.: Farmakoterapia bólu neuropatycznego. „Medycyna Paliatywna w Praktyce”, 2017, 11, 262.
16. Monteiro B.P., Lascelles B.D.X., Murrell J., Robertson S., Steagall P.V.M., Wright B.: 2022 WSAVA guidelines for the recognition, assessment, and treatment of pain. „Journal of Small Animal Practice”, 2022.
17. Attal N., Bouhassira D.: Pharmacotherapy of neuropathic pain: which drugs, which treatment algorithms? „Pain”, 2015, 156, 1, S104-S114, DOI: 10.1097/01.j.pain.0000460358.01998.15 (Indexed in Pubmed: 25789426).
18. Cashmore R.G., Harcourt-Brown T.R., Freeman P.M., Jeffery N.D., Granger N.: Clinical diagnosis, and treatment of suspected neuropathic pain in three dogs. „Aust Vet J”, 2009, 87, 45-50. DOI: 10.1111/j.1751-0813.2008. 00379.x.
19. Kukanich B., Cohen R.L.: Pharmacokinetics of oral gabapentin in greyhound dogs. „Vet J”, 2011, 187 (1), 133-135.
20. Siao K.T., Pypendop B.H., Ilkiw J.E.: Pharmacokinetics of gabapentin in cats. „Am J Vet Res”, 2010, 71 (7), 817-821.
21. Bockbrader H.N., Wesche D., Miller R. et al.: A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. „Clin Pharmacokinet”, 2010, 49 (10), 661-669.
22. Gidal B.E., Maly M.M., Kowalski J.W. et al.: Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. „Ann Pharmacother”, 1998, 32, 405-409.
23. Crociolli G.C., Cassu R.N., Barbero R.C. et al.: Gabapentin as an adjuvant for postoperative pain management in dogs undergoing mastectomy. „J Vet Med Sci”, 2015, 77, 1011-1015.
24. Wagner A.E., Mich P.M., Uhrig S.R., Hellyer P.W.: Clinical evaluation of perioperative administration of gabapentin as an adjunct for postoperative analgesia in dogs undergoing amputation of a forelimb. „J Am Vet Med Assoc”, 2010, 236 (7), 751-6. DOI: 10.2460/javma.236.7.751.
25. Salazar V., Dewey C.W., Schwark W., Badgley B.L., Gleed R.D., Horne W. et al.: Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. „Vet Anaesth Analg”, 2009, 36, 574-80. DOI: 10.1111/j.1467-2995.2009. 00486.x.
26. Esteban M.A., Dewey C.W., Schwark W.S., Rishniw M., Boothe D.M.: Pharmacokinetics of Single-Dose Oral Pregabalin Administration in Normal Cats. „Frontiers in Veterinary Science”, 2018, 5, 136. DOI: https://doi.org/10.3389/fvets.2018.00136.
27. Lamminen T., Doedée A., HyttiläHopponen M., Kaskinoro J.: Pharmacokinetics of single and repeated oral doses of pregabalin oral solution formulation in cats. „Journal of Veterinary Pharmacology and Therapeutics”, 2022, 45, 385-391. DOI: https://doi.org/10.1111/jvp.13061.
28. Thoefnera M.S., Skovgaardb L.T., McEvoya F.J., Berendta M., Bjerrum O.J.: Pregabalin alleviates clinical signs of syringomyelia-related central neuropathic pain in Cavalier King Charles Spaniel dogs: a randomized controlled trial. „Veterinary Anaesthesia and Analgesia”, 2020, 47, 238e248. DOI: https://doi.org/10.1016/j.vaa.2019.09.007238.
29. Chew D.J., Buffington C.A., Kendall M.S., DiBartola S.P., Woodworth B.E.: Amitriptyline treatment for severe recurrent idiopathic cystitis in cats. „J Am Vet Med Assoc”, 1998, 213 (9), 1282-6.
30. Kukes V.G., Kondratenko S.N., Savelyeva M.I., Starodubtsev A.K., Gneushev E.T.: Experimental and clinical pharmacokinetics of amitryptiline: comparative analysis. „Bull Exp Biol Med”, 2009, 147, 434-7. DOI: 10.1007/s10517-009-0520-4.
31. Monteiro B.P., de Lorimier L.P., Moreau M., Beauchamp G., Blair J., Lussier B., Pelletier J.P., Troncy E.: Pain characterization and response to palliative care in dogs with naturally occurring appendicular osteosarcoma: An open label clinical trial. „PLoS One”, 2018, 13 (12): e0207200. DOI: 10.1371/journal.pone.0207200.
32. Steagall P., Robertson S.A., Taylor P.: Feline Anesthesia and Pain Management. WILEY Blackwell, 2017.
33. Perez Jimenez T.E., Mealey K.L., Grubb T.L., Greene S.A., Court M.H.: Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs). ”Drug Metab Dispos”, 2016, 44 (12), 1963-1972./[published correction appears in] „Drug Metab Dispos”, 2017, 45 (7), 706. DOI: 10.1124/dmd.116.071902.
34. Lavand’homme P., Thienpont E.: Pain after total knee arthroplasty: a narrative review focusing on the stratification of patients at risk for persistent pain. „Bone Joint J”, 2015, 97-B, 45-8. DOI: 10.1302/0301-620X.97B10.36524.
35. Lyons P.J., Rivosecchi R.M., Nery J.P., Kane-Gill S.L.: Fentanyl-induced hyperalgesia in acute pain management. „J Pain Palliat Care Pharmacother”, 2015, 29 (2), 153-60. DOI: 10.3109/15360288.2015.1035835. PMID: 26095487.
36. Santonocito C., Noto A., Crimi C., Sanfilippo F.: Remifentanil-induced postoperative hyperalgesia: current perspectives on mechanisms and therapeutic strategies. „Local Reg Anesth.”, 2018, 11, 15-23. DOI: 10.2147/LRA.S143618 (Published 2018 Apr 9).
37. KuKanich B., Papich M.G.: Pharmacokinetics of tramadol and the metabolite O-desmethyltramadol in dogs. „J Vet Pharmacol Ther”, 2004, 27, 239-246.
38. Monteiro B.P., Klinck M.P., Moreau M., Guillot M., Steagall P.V., Pelletier J.P., Martel-Pelletier J., Gauvin D., Del Castillo J.R., Troncy E.: Analgesic efficacy of tramadol in cats with naturally occurring osteoarthritis. „PLoS One”, 2017, 12 (4), e0175565. DOI: 10.1371/journal.pone.0175565.
39. Guedes A.G.P., Meadows J.M., Pypendop B.H., Johnson E.G.: Evaluation of tramadol for treatment of osteoarthritis in geriatric cats. „J Am Vet Med Assoc”, 2018 Mar 1, 252 (5), 565-571. doi: 10.2460/javma.252.5.565. PMID: 29461159.
40. Domínguez-Oliva A., Casas-Alvarado A., Miranda-Cortés A.E., Hernández-Avalos I.: Clinical pharmacology of tramadol and tapentadol, and their therapeutic efficacy in different models of acute and chronic pain in dogs and cats. „J Adv Vet Anim Res”, 2021, 8 (3), 404-422. DOI: 10.5455/javar.2021.h529 (Published 2021 Sep 19).
41. Siao K.T., Pypendop B.H., Stanley S.D.: Pharmacokinetics of amantadine in cats. „J Vet Pharmacol Ther”, 2011, 34, 599-604.
42. Lascelles B.D., Gaynor J.S., Smith E.S. et al.: Amantadine in a multimodal analgesic regimen for alleviation of refractory osteoarthritis pain in dogs. „J Vet Intern Med”, 2008, 22 (1), 53-59.
43. Cimino Brown D.: Resiniferatoxin: The Evolution of the „Molecular Scalpel” for Chronic Pain Relief. „Pharmaceuticals”, 2016, 9 (3), 47.
44. Koppel B.S., Brust J.C., Fife T., Bronstein J., Youssof S., Gronseth G. et al.: Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development subcommittee of the American Academy of Neurology. „Neurology”, 2014, 82, 1556-63. DOI: 10.1212/ WNL.0000000000000363.
45. Tauben D.: Nonopioid medications for pain. „Phys Med Rehabil Clin N Am”, 2015, 26, 219-48. DOI: 10.1016/j.pmr.2015.01.005.
46. Karlik W.: Co lekarz weterynarii powinien wiedzieć o produktach z konopi. „Magazyn Weterynaryjny”, 2020.
47. Pascual D. et al.: A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats. „Pain”, 2005, 118, 1-2.
48. Xiong W. et al.: Administration of cannabidiol (indirect antagonist of CB1 and CB2 receptor agonists) significantly suppressed chronic inflammatory and neuropathic pain in rodents. 2012.
49. Gamble L.J., Boesch J.M., Frye C.W., Schwark W.S., Mann S., Wolfe L., Brown H., Berthelsen E.S., Wakshlag J.J.: Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs. „Front Vet Sci”, 2018, 5, 165. DOI: 10.3389/fvets.2018.00165.
50. Wilson-Morkeh H., Al-Abdulla A., Sien L., Mohamed H., Youngstein T.: Important drug interactions exist between cannabidiol oil and commonly prescribed drugs in rheumatology practice. „Rheumatology”, 2020, 59, 1, 249-251. DOI: https://doi.org/10.1093/rheumatology/kez304.
51. della Rocca G., Gamba D.: Chronic Pain in Dogs and Cats: Is There Place for Dietary Intervention with Micro-Palmitoylethanolamide? „Animals”, 2021, 11 (4), 952. DOI: https://doi.org/10.3390/ani11040952.
52. 52.    Enomoto M., Mantyh P.W., Murrell J., Innes J.F., Lascelles B.D.X.: Anti-nerve growth factor monoclonal antibodies for the control of pain in dogs and cats. „Vet Rec”, 2019, 184 (1), 23. DOI: 10.1136/vr.104590.
53. Krautmann M., Walters R., Cole P., Tena J., Bergeron L.M., Messamore J., Mwangi D., Rai S., Dominowski P., Saad K., Zhu Y., Guillot M., Chouinard L.: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs. „The Veterinary Journal”, 2021, 276, 105733. DOI: https://doi.org/10.1016/j.tvjl.2021.105733.
54. Goich M., Bascuńán A., Faúndez P., Valdés A.: Multimodal analgesia for treatment of allodynia and hyperalgesia after major trauma in a cat. „JFMS Open Rep”, 2019, 5 (1), 2055116919855809. DOI: 10.1177/2055116919855809 (Published 2019 Jun 18).

lek. wet. Zofia Fraś
Przychodnia Weterynaryjna „BIAŁOBRZESKA”
ul. Częstochowska 20 02-344 Warszawa